N-acetyltransferase 2 and bladder cancer: An overview and consideration of the evidence for gene-environment interaction

British Journal of Cancer

Volumn 83, Issue 3, 2000, Pages 412-417

  Green, J ^a   Banks, E ^a   Berrington, A ^a   Darby, S ^a   Deo, H ^a   Newton, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Arylamines; Bladder cancer; Gene environment interaction; Genetic polymorphism; NAT2; Smoking

Indexed keywords

ACYLTRANSFERASE; AROMATIC AMINE; CARCINOGEN;

ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; OCCUPATIONAL EXPOSURE; PHENOTYPE; PRIORITY JOURNAL; SMOKING;

ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK; RISK FACTORS; SMOKING; TOBACCO SMOKE POLLUTION; URINARY BLADDER NEOPLASMS;

EID: 0033938764     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1265     Document Type: Article

References (55)

1. Bidio MP, Breitenfeld L, Carvalho AA and Manso CF (1988) Acetylation phenotypes in patients with bladder carcinoma. Ann Genet 31: 167-171
2. Brockmöller J, Cascorbi I, Kerb R and Roots I (1996) Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases MI and TI, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56: 3915-3925
3. Cartwright RA (1979) Genetic association with bladder cancer. BMJ 2: 798
4. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E and Kahn MA (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2: 842-845
5. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K and Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57: 581-592
6. Case RA, Hosker ME, McDonald DB and Pearson JT (1954) Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. British Journal of Industrial Medicine 11: 75-104
7. Cox DR and Snell EJ (1989) Analysis of Binary Data, p. 60. Chapman and Hall: London
8. Cuzick J (1999) Interaction, subgroup analysis and sample size. In: Metabolic Polymorphisms and Susceptibility to Cancer, Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds). pp. 109-121. International Agency for Research on Cancer: Lyon
9. d'Errico A, Taioli E, Chen X and Vineis P (1996) Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1: 149-173
10. d'Errico A, Malats N, Vineis P and Boffetta P (1999) Review of studies of selected metabolic polymorphisms and cancer. In: Metabolic Polymorphisms and Susceptibility to Cancer, Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds). pp. 323-393. International Agency for Research on Cancer: Lyon
11. Dewan A, Chattopadhyay P and Kulkami PK (1995) N-acetyltransferase activity - a susceptibility factor in human bladder carcinogenesis. Indian J Cancer 32: 15-19
12. Egger M, Schneider M and Davey Smith G (1998) Meta-analysis: Spurious precision? Meta-analysis of observational studies. BMJ 316: 140-144
13. Evans DAP, Eze LC and Whibley EJ (1983) The association of the slow acelylator phenotype with bladder cancer. J Med Genet 20: 330-333
14. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL and Grewal R (1997) Human acetyltransferase polymorphisms. Mutat Res 376: 61-70
15. Hanke J and Krajewska B (1990) Acetylation phenotypes and bladder cancer. Journal of Occupational Medicine 32: 917-918
16. Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W and Ovenbeck R (1985) Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. Eur Urol 11: 263-266
17. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL and Meyer UA (1993) N-Acetylation phenotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 14: 675-678
18. Hein DW (1998) Acetylator phenotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948: 37-66
19. Hirvonen A (1999) Polymorphic NATs and cancer predisposition. In: Metabolic Polymorphisms and Susceptibility to Cancer, Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds). pp. 251-270. International Agency for Research on Cancer: Lyon
20. Horai Y, Fujita K and Ishizaki T (1989) Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 37: 581-587
21. Hwang S-J, Beaty TH, Liang K-L, Coresh J and Khoury MJ (1994) Minimum sample size estimation to detect gene-environment interaction in case-control designs. Am J Epidemiol, 140: 1029-1037
22. Ishizu S, Hashida C, Hanaoka T, Maeda K and Ohishi Y (1995) N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. Jpn J Cancer Res 86: 1179-1181
23. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA and Branch RA (1987) Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 47: 5488-5493
24. Kalo R, Estabrook RW and Cayen MN (eds) pp 449-506. Taylor and Francis: London
25. Kantor AF, Hartge P, Hoover RN and Fraumeni JF Jr (1985) Familial and environmental interactions in bladder cancer risk. Int J Cancer 35: 703-706
26. Karakaya AE, Cok I, Sardas S, Gogus O and Sardas OS (1986) N-Acetyltransferase phenotype of patients with bladder cancer. Human Toxicology 5: 333-335
27. Kiemeny LA, Moret NC, Witjes JA, Schoenberg MP and Tulinius H (1997) Familial transitional cell carcinoma among the population of Iceland. J Urol 157: 1649-1651
28. Knowles MA (1998) Molecular genetics of bladder cancer: pathways of development and progression. In: Cancer Surveys 31: Bladder Cancer, Oliver RTD, Coptcoal MJ (eds), pp. 49-76. Imperial Cancer Research Fund-Cold Spring Harbour Laboratory Press: New York
29. Ladero JM, Kwok CK, Jara C, Fernandez L, Silmi AM, Tapia D and Uson AC (1985) Hepatic acetylator phenotype in bladder cancer patients. Annals of Clinical Research 17: 96-99
30. Lee SW, Jang IJ, Shin SG, Lee KH, Yim DS, Kim SW, Oh SJ and Lee SH (1994) CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci 9: 482-489
31. Le Marchand LL, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens A and Lau AF (1998) Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58: 4858-4863
32. Lin HJ, Han C-Y, Lin BK and Hardy S (1994) Ethnic distribution of slow acetylator mutations in the polymorphic N-acelyltransferase (NAT2) gene. Pharmacogenetics 4: 125-134
33. Lower GM, Jr., Nilsson T, Nelson CE, Wolf H, Gamsky TE and Bryan GT (1979) N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29: 71-79
34. Miller ME and Cosgriff JM (1983) Acetylator phenotype in human bladder cancer. J Urol 130: 65-66
35. Mommsen S, Barfod NM and Aagaard J (1985) N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 6: 199-201
36. Okkels H, Sigsgaard T, Wolf H and Autrup H (1997) Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 6: 225-231
37. Oxman AD and Guyatt GH (1992) A consumer's guide to subgroup analysis. Ann Intern Med 116: 79-84
38. Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, Giacomelli G, Terrone C, Casetta G and Vineis P (1998) White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 7: 341-346
39. Probert JL, Persad RA, Greenwood RP, Gillatt DA and Smith PJB (1998) Epidemiology of transitional cell carcinoma of the bladder: profile of an urban population in the south-west of England. Br J Urol 82: 660-666
40. Risch A, Wallace DM, Bathers S and Sim E (1995) Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4: 231-236
41. Roots I, Drakoulis N, Brockmöller J, Janicke I, Cuprunov M and Ritter J (1989) Hydroxylation and acetylation phenotypes as genetic risk factors in certain malignancies. In: Kato R, Estabrook RW and Cayen MN (eds) Xenobiotic Metabolism and Disposition. pp 499-506. Taylor and Francis: London
42. Rothman N, Garcia-Closas M, Stewart WT and Lubin J (1999) The impact of misclassification in case-control studies of gene-environment interactions. In: Metabolic Polymorphisms and Susceptibility to Cancer, Vineis P, Malats N. Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds). pp. 89-96. International Agency for Research on Cancer: Lyon
43. Silverman DT, Morrison AS and Devesa SS (1996) Bladder cancer. In: Cancer Epidemiology and Prevention, Schottenfeld D, Fraumeni JE (eds), pp. 1156-1179. OUP: New York, Oxford
44. Smith CAD, Wadelius M, Gough AC, Harrison DJ, Wolf CR and Rane A (1997) A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 34: 758-760
45. Sone M (1986) [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls]. [Japanese]. Hinyokika Kiyo 32: 1085-1092
46. WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines. Br J Cancer 77: 1573-1579
47. Su HJ, Guo YL, Lai M-D, Huang J-D, Cheng Y and Christiani DC (1998) The NAT2* slow genotype is associated with bladder cancer in Taiwanese, but not in the Black Foot Disease endemic area population. Pharmacogenetics 8: 187-190
48. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL and Bell DA (1998) The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 58: 3603-3610
49. Vatsis KP, Weber WW, Bell DA. Dupret J-M, Price Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T and Yamazoe Y (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5: 1-17
50. Vineis P (1992) Epidemiological models of carcinogenesis: the example of bladder cancer. Cancer Epidemiol Biomarkers Prev 1: 149-153
51. Vineis P, Malats N, Lang M, d'Errico A, Caporaso N and Boffetta P (eds) (1999) Metabolic Polymorphisms and Susceptibility to Cancer. International Agency for Research on Cancer: Lyon
52. Whiteman DC, Parsons PG and Green A (1998) p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 77: 843-848
53. Woodhouse KW, Adams P, Clothier A, Mucklow J and Rawlins MD (1982) N-acetylation phenotype in bladder cancer. Human Toxicology 1: 443-445
54. Woolhouse NM, Qureshi MM, Bastaki SMA, Patel M, Abdulrazzaq Y and Bayoumi RAL (1997) Polymorphic N-acetylransferase (NAT2) genotyping of Emiratis. Pharmacogenetics 7: 73-82
55. Xie H-G, Xu Z-H, Ou-Yang D-S, Shu Y, Yang D-L, Wang J-S, Yan Z-D, Huang S-L, Wang W and Zhou H-H (1997) Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 7: 503-514